Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 559

1.

Rotavirus vaccination and intussusception - science, surveillance, and safety: a review of evidence and recommendations for future research priorities in low and middle income countries.

Yen C, Healy K, Tate JE, Parashar UD, Bines J, Neuzil K, Santosham M, Steele AD.

Hum Vaccin Immunother. 2016 Jun 20:0. [Epub ahead of print]

PMID:
27322835
2.

Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention.

Moro PL, Li R, Haber P, Weintraub E, Cano M.

Expert Opin Drug Saf. 2016 Jun 16:1-9. [Epub ahead of print]

PMID:
27268157
3.

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid).

Esposito S, Bonanni P, Maggi S, Tan L, Ansaldi F, Lopalco PL, Dagan R, Michel JP, van Damme P, Gaillat J, Prymula R, Vesikari T, Mussini C, Frank U, Osterhaus A, Celentano LP, Rossi M, Guercio V, Gavazzi G.

Hum Vaccin Immunother. 2016 May 2:1-18. [Epub ahead of print]

PMID:
27135390
4.

Improving Immunization Rates Through Community-Based Participatory Research: Community Health Improvement for Milwaukee's Children Program.

Willis E, Sabnis S, Hamilton C, Xiong F, Coleman K, Dellinger M, Watts M, Cox R, Harrell J, Smith D, Nugent M, Simpson P.

Prog Community Health Partnersh. 2016 Spring;10(1):19-30. doi: 10.1353/cpr.2016.0009.

5.

Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).

Silfverdal SA, Coremans V, François N, Borys D, Cleerbout J.

Expert Rev Vaccines. 2016 Mar 8. [Epub ahead of print]

PMID:
26954689
6.

INFECTIOUS DISEASE. The race for a Zika vaccine is on.

Cohen J.

Science. 2016 Feb 5;351(6273):543-4. doi: 10.1126/science.351.6273.543. No abstract available.

PMID:
26912676
7.

SAFETY OF A CRM197-CONJUGATED HAEMOPHILUS INFLUENZAE TYPE B VACCINE IN KOREAN CHILDREN.

Song H, Bock H, Guadagno A, Costantini M, Baehner F, Kim YH, Ahn SI, Son KH, Yim DS.

Southeast Asian J Trop Med Public Health. 2015 Jul;46(4):743-52.

PMID:
26867395
8.

Pattern of anti-diabetic drugs prescribed in a tertiary care hospital of Bangladesh.

Ahmed Z, Hafez MA, Bari MA, Akhter J.

Int J Basic Clin Pharmacol. 2016 Jan-Feb;5(1):6-12. Epub 2016 Jan 28.

9.

Vaccine hesitancy: understanding better to address better.

Kumar D, Chandra R, Mathur M, Samdariya S, Kapoor N.

Isr J Health Policy Res. 2016 Feb 1;5:2. doi: 10.1186/s13584-016-0062-y. eCollection 2016.

10.

Post-Marketing Benefit-Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis.

Ledent E, Lieftucht A, Buyse H, Sugiyama K, Mckenna M, Holl K.

Drug Saf. 2016 Mar;39(3):219-30. doi: 10.1007/s40264-015-0376-7.

11.

Future pandemics and vaccination: Public opinion and attitudes across three European countries.

Determann D, de Bekker-Grob EW, French J, Voeten HA, Richardus JH, Das E, Korfage IJ.

Vaccine. 2016 Feb 3;34(6):803-8. doi: 10.1016/j.vaccine.2015.12.035. Epub 2015 Dec 28.

12.
13.

[Implementation of meningococcal B vaccination (Bexsero®) in France: Physicians' perceptions and experiences of a few months after marketing approval].

Levy C, Bechet S, Cohen R.

Arch Pediatr. 2016 Jan;23(1):27-33. doi: 10.1016/j.arcped.2015.09.011. Epub 2015 Oct 23. French.

PMID:
26603630
14.

Cross-sectional study about primary health care professionals views on the inclusion of the vaccine against human papillomavirus in the vaccine schedules.

Pérez MR, Violeta VB, Del Campo AV, Ruiz C, Castaño SY, Conde LP, López JS.

Infect Agent Cancer. 2015 Nov 16;10:41. doi: 10.1186/s13027-015-0034-9. eCollection 2015.

15.

Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries.

Dellepiane N, Akanmori BD, Gairola S, Jadhav SS, Parker C, Rodriguez C, Srivastava S.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S428-33. doi: 10.1093/cid/civ491.

16.

Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia.

Regan AK, Tracey L, Gibbs R.

Vaccine. 2015 Nov 17;33(46):6149-51. doi: 10.1016/j.vaccine.2015.10.005. Epub 2015 Oct 21.

PMID:
26476362
17.

Freeze-dried live attenuated smallpox vaccine prepared in cell culture "LC16-KAKETSUKEN": Post-marketing surveillance study on safety and efficacy compliant with Good Clinical Practice.

Nishiyama Y, Fujii T, Kanatani Y, Shinmura Y, Yokote H, Hashizume S.

Vaccine. 2015 Nov 9;33(45):6120-7. doi: 10.1016/j.vaccine.2015.09.067. Epub 2015 Oct 9.

18.

Selling Health to the Distracted: Consumer Responses to Source Credibility and Ad Appeal Type in a Direct-to-Consumer Advertisement.

Lemanski JL, Villegas J.

Health Mark Q. 2015;32(3):217-33. doi: 10.1080/07359683.2015.1061847.

PMID:
26368298
19.

Cost-Effectiveness Analysis of a Television Campaign to Promote Seasonal Influenza Vaccination Among the Elderly.

Kim M, Yoo BK.

Value Health. 2015 Jul;18(5):622-30. doi: 10.1016/j.jval.2015.03.1794. Epub 2015 Jul 7.

PMID:
26297090
20.

Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.

Toh ZQ, Licciardi PV, Fong J, Garland SM, Tabrizi SN, Russell FM, Mulholland EK.

Vaccine. 2015 Sep 22;33(39):5042-50. doi: 10.1016/j.vaccine.2015.07.102. Epub 2015 Aug 10. Review.

PMID:
26271829
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk